These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 9605741

  • 1. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer.
    Gratas C, Tohma Y, Barnas C, Taniere P, Hainaut P, Ohgaki H.
    Cancer Res; 1998 May 15; 58(10):2057-62. PubMed ID: 9605741
    [Abstract] [Full Text] [Related]

  • 2. Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer.
    Müllauer L, Mosberger I, Grusch M, Rudas M, Chott A.
    J Pathol; 2000 Jan 15; 190(1):20-30. PubMed ID: 10640988
    [Abstract] [Full Text] [Related]

  • 3. Expression of Fas and Fas ligand in esophageal tissue mucosa and carcinomas.
    Kase S, Osaki M, Adachi H, Kaibara N, Ito H.
    Int J Oncol; 2002 Feb 15; 20(2):291-7. PubMed ID: 11788891
    [Abstract] [Full Text] [Related]

  • 4. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma.
    Viard-Leveugle I, Veyrenc S, French LE, Brambilla C, Brambilla E.
    J Pathol; 2003 Oct 15; 201(2):268-77. PubMed ID: 14517844
    [Abstract] [Full Text] [Related]

  • 5. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
    Bennett MW, O'Connell J, O'Sullivan GC, Brady C, Roche D, Collins JK, Shanahan F.
    J Immunol; 1998 Jun 01; 160(11):5669-75. PubMed ID: 9605174
    [Abstract] [Full Text] [Related]

  • 6. Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer.
    Shibakita M, Tachibana M, Dhar DK, Kotoh T, Kinugasa S, Kubota H, Masunaga R, Nagasue N.
    Clin Cancer Res; 1999 Sep 01; 5(9):2464-9. PubMed ID: 10499620
    [Abstract] [Full Text] [Related]

  • 7. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes.
    Gastman BR, Atarshi Y, Reichert TE, Saito T, Balkir L, Rabinowich H, Whiteside TL.
    Cancer Res; 1999 Oct 15; 59(20):5356-64. PubMed ID: 10537320
    [Abstract] [Full Text] [Related]

  • 8. The breakdown of apoptotic mechanism in the development and progression of colorectal carcinoma.
    Ogawa S, Nagao M, Kanehiro H, Hisanaga M, Ko S, Ikeda N, Nakajima Y.
    Anticancer Res; 2004 Oct 15; 24(3a):1569-79. PubMed ID: 15274324
    [Abstract] [Full Text] [Related]

  • 9. Fas ligand expression in esophageal carcinomas and their lymph node metastases.
    Younes M, Schwartz MR, Ertan A, Finnie D, Younes A.
    Cancer; 2000 Feb 01; 88(3):524-8. PubMed ID: 10649242
    [Abstract] [Full Text] [Related]

  • 10. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes.
    Kim JW, Wieckowski E, Taylor DD, Reichert TE, Watkins S, Whiteside TL.
    Clin Cancer Res; 2005 Feb 01; 11(3):1010-20. PubMed ID: 15709166
    [Abstract] [Full Text] [Related]

  • 11. Increased Fas ligand expression by T cells and tumour cells in the progression of actinic keratosis to squamous cell carcinoma.
    Satchell AC, Barnetson RS, Halliday GM.
    Br J Dermatol; 2004 Jul 01; 151(1):42-9. PubMed ID: 15270871
    [Abstract] [Full Text] [Related]

  • 12. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis.
    Ungefroren H, Voss M, Jansen M, Roeder C, Henne-Bruns D, Kremer B, Kalthoff H.
    Cancer Res; 1998 Apr 15; 58(8):1741-9. PubMed ID: 9563493
    [Abstract] [Full Text] [Related]

  • 13. Fas ligand is constitutively secreted by prostate cancer cells in vitro.
    Liu QY, Rubin MA, Omene C, Lederman S, Stein CA.
    Clin Cancer Res; 1998 Jul 15; 4(7):1803-11. PubMed ID: 9676859
    [Abstract] [Full Text] [Related]

  • 14. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo?
    Nagao M, Nakajima Y, Hisanaga M, Kayagaki N, Kanehiro H, Aomatsu Y, Ko S, Yagita H, Yamada T, Okumura K, Nakano H.
    Hepatology; 1999 Aug 15; 30(2):413-21. PubMed ID: 10421649
    [Abstract] [Full Text] [Related]

  • 15. Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR.
    Das H, Koizumi T, Sugimoto T, Chakraborty S, Ichimura T, Hasegawa K, Nishimura R.
    Br J Cancer; 2000 May 15; 82(10):1682-8. PubMed ID: 10817504
    [Abstract] [Full Text] [Related]

  • 16. Expression of Fas and Fas-related molecules in human hepatocellular carcinoma.
    Lee SH, Shin MS, Lee HS, Bae JH, Lee HK, Kim HS, Kim SY, Jang JJ, Joo M, Kang YK, Park WS, Park JY, Oh RR, Han SY, Lee JH, Kim SH, Lee JY, Yoo NJ.
    Hum Pathol; 2001 Mar 15; 32(3):250-6. PubMed ID: 11274632
    [Abstract] [Full Text] [Related]

  • 17. Up-regulation of fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance.
    Shimonishi T, Isse K, Shibata F, Aburatani I, Tsuneyama K, Sabit H, Harada K, Miyazaki K, Nakanuma Y.
    Hepatology; 2000 Oct 15; 32(4 Pt 1):761-9. PubMed ID: 11003620
    [Abstract] [Full Text] [Related]

  • 18. c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations.
    Korkolopoulou P, Goudopoulou A, Voutsinas G, Thomas-Tsagli E, Kapralos P, Patsouris E, Saetta AA.
    Urology; 2004 Jun 15; 63(6):1198-204. PubMed ID: 15183989
    [Abstract] [Full Text] [Related]

  • 19. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
    Mitsiades N, Poulaki V, Tseleni-Balafouta S, Koutras DA, Stamenkovic I.
    Cancer Res; 2000 Aug 01; 60(15):4122-9. PubMed ID: 10945619
    [Abstract] [Full Text] [Related]

  • 20. Expression of Fas and Fas ligand in cutaneous B-cell lymphomas.
    Zoi-Toli O, Meijer CJ, Oudejans JJ, de Vries E, van Beek P, Willemze R.
    J Pathol; 1999 Dec 01; 189(4):533-8. PubMed ID: 10629554
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.